The BETR-Disinfection Study – The Ultimate “Outcome” Study
In the hierarchy of clinical studies, randomized clinical trials are one of the most trusted types and often have the ability to change health care standards and guidelines. The first and only randomized clinical trial on UVC disinfection was conducted from 2012-2014 throughout the Duke Infection Control Outreach Network and funded by the Centers for Disease Control and Prevention. Tru-D was the only UVC device selected for the BETR-Disinfection study due to its ability to eliminate human error in the disinfection process and establish a solid baseline of disinfection.
The BETR-Disinfection study was designed to examine the impact of enhanced terminal room disinfection as a method to prevent hospital-acquired infections (HAIs). The most comprehensive study on UVC disinfection to date, the BETR-D study was a cluster randomized, multicenter crossover study with 2×2 factorial design to evaluate the impact of enhanced terminal room disinfection on acquisition and infection caused by multidrug-resistant organisms (MDROs).
Results proved that enhanced terminal room disinfection strategies reduced the cumulative relative risk of acquisition of targeted MDROs by 30%, and the largest decreases were seen when Tru-D was added to the standard cleaning protocols with quaternary ammonium. Although the primary outcome did not find a reduction for C. diff, supplementary data in this initial paper found that there was a reduction in incidence of C. diff between the study groups, with lower incidence found when UVC was added to standard cleaning protocols. This reduction was confirmed by a secondary analysis in a subsequent paper (more to come in a later post).
In contrast to virtually every other study on UVC, including some studying Tru-D – this was a highly-controlled and monitored study and not a simple before/after analysis in which confounding factors can sometimes mask or falsely amplify results. Tru-D’s sole inclusion in this type of study has provided the unique ability to validate our disinfection claims at the highest level and prove that mobile UVC disinfection isn’t just a novel idea – it’s a clinically-validated disinfection method proven to reduce infections.
The bottom line is that the BETR-Disinfection study proved that Tru-D has a direct impact on the next patient who enters a room, resulting in a 30% reduction in the transmission of MDROs, and a cleaner, safer environment for that next patient.
Stay tuned for next week’s post on the secondary analysis of the BETR-D study and how Tru-D can impact every patient in the hospital.